MediWound (MDWD) announced the publication of its Phase III Children Innovative Debridement Study in Burns, the peer-reviewed Journal of the ...

NexoBrid ® is a topically administered biological orphan drug that enzymatically removes eschar while preserving viable ...

In addition, the MediWound management team will host one-on-one meetings during the conference. Interested investors are encouraged to contact their TD Cowen representative to schedule a meeting.